The IGF1R Knockout Jurkat Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat T-lymphoblastoid cell line, featuring targeted disruption of the IGF1R gene. This polyclonal population provides a heterogeneous gene-edited pool suitable for studying loss-of-function effects without clonal selection bias.
The parental Jurkat cell line is an immortalized human T lymphoblastoid line originally established from an acute T-cell leukemia patient. Jurkat cells retain key characteristics of T lymphocytes and have been extensively utilized as a model system for investigating T-cell receptor signaling, immune response mechanisms, and leukemogenesis. Their robust growth in suspension culture and well-characterized signaling networks make them an ideal host for genetic modification studies.
IGF1R encodes a receptor tyrosine kinase that binds insulin-like growth factors IGF1 and IGF2, triggering intracellular phosphorylation cascades. Upon ligand engagement, IGF1R autophosphorylates and recruits adaptor proteins such as IRS1 and SHC, which in turn activate the PI3K/AKT and MAPK/ERK pathways. Specifically, the IGF1R?CIRS1?CPI3K?CAKT axis stimulates mTOR signaling, promoting protein synthesis and cell growth, while the SHC/Grb2/SOS?CRAS?CRAF?CMEK?CERK cascade drives cell cycle progression via induction of Cyclin D1. AKT also phosphorylates and inactivates pro-apoptotic BAD and FOXO transcription factors, enhancing cell survival. In Jurkat cells, IGF1R signaling also intersects with JAK/STAT pathways, contributing to cytokine-mediated proliferation. Knockout of IGF1R disrupts these networks, abrogating downstream phosphorylation of AKT, ERK1/2, and other effectors.
In the Jurkat T-cell leukemia context, IGF1R plays a pivotal role in sustaining malignant proliferation and resisting apoptosis. Loss of IGF1R function in these polyclonal knockout cells mimics therapeutic inhibition, rendering them hypersensitive to apoptotic stimuli and reducing clonogenic growth. This model system enables dissection of IGF1R-dependent versus -independent survival signals, particularly relevant for T-cell malignancies where IGF1R overexpression is linked to poor prognosis.
Researchers can employ this polyclonal IGF1R KO Jurkat population for a broad spectrum of applications. It serves as a robust platform for studying IGF1R signaling dynamics in leukemia, evaluating novel IGF1R-targeted small molecules or biologics, and examining crosstalk between insulin/IGF receptors. Functional assays may include phospho-signaling analysis via Western blot (e.g., p-AKT, p-ERK), apoptosis measurement by Annexin V flow cytometry, proliferation assays using CFSE dilution or MTS, and gene expression profiling by RT-qPCR for downstream targets like Cyclin D1 or FOXO1. The product is suitable for pathway inhibitor studies, signaling complex co-immunoprecipitation, and high-throughput drug screens. For technical inquiries or customized solutions, please contact Ascent Research.
